ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BMS' Opdivo fails to win over NICE as adjuvant melanoma therapy
September 13, 2018Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an adjuvant treatment of completely... -
BMS' Opdivo scores eighth approval in Europe for bladder cancer
June 06, 2017Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the European Commission accepts the drug for the treatment of locally-advanced unresectable or metastatic urotheli
Pharma Sources Insight January 2025
